Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.

Clinical journal of the American Society of Nephrology : CJASN - 1 Mar 2014

Hoyer-Kuhn Heike, Kohbrok Sina, Volland Ruth, Franklin Jeremy, Hero Barbara, Beck Bodo B, Hoppe Bernd

Abstract excerpt

BACKGROUND AND OBJECTIVES: Primary hyperoxaluria type I (PH I) is caused by deficiency of the liver-specific enzyme alanine-glyoxylate:aminotransferase (AGT). Many mutations are known to perturb AGT protein folding. Vitamin B6 (B6) is the only specific drug available for treatment. Although B6 has been used for >40 years, controlled data on B6 efficacy are lacking. Therefore, this study investigated the absolute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germany

Share to Homozygote

Share to Hyperoxaluria, Primary

Share to Transaminases

Share to Treatment Outcome

Share to Vitamin B 6

Source

Open in PubMed Open full text

Identifiers

PMID: 24385516
DOI: 10.2215/CJN.06820613
PMCID: PMC3944765

Genes

AGT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.PMID 24385516Read ↗

Molecular etiology of primary hyperoxaluria type 1: new directions for treatment.Semantic proximity Read ↗

Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.Semantic proximity Read ↗

Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I.Semantic proximity Read ↗

An update on primary hyperoxaluria.Semantic proximity Read ↗

Primary hyperoxaluria: insights into its clinical presentation, genetic mutations, and transplantation outcomes in a pediatric population in a tertiary care center.Semantic proximity Read ↗

Primary hyperoxalurias: diagnosis and treatment.Semantic proximity Read ↗

[Primary hyperoxaluria].Semantic proximity Read ↗

Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria.Semantic proximity Read ↗

The primary hyperoxalurias.Semantic proximity Read ↗

Molecular Aetiology of Primary Hyperoxaluria Type 1Semantic proximity Read ↗

A molecular journey on the pathogenesis of primary hyperoxaluria.Semantic proximity Read ↗

Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.